Provided are liquid sustained release pharmaceutical formulations for delivery of active pharmaceutical ingredients to the eye. The formulations are particularly suitable for delivering proteins to the eye such as bovine gamma globulin. The formulations comprise at least one liquid biodegradable non-polymeric excipient, such as acetyl triethyl citrate (ATEC) or dimethyl sulfoxide (DMSO), and at least one biodegradable, biocompatible poly(D,L-lactide) (PLA) and/or poly(D,L-lactide-co-glycolide) (PLGA) polymer, wherein the ratio of non-polymeric excipient: polymer is about 90:10 to about 99:1. Further provided is the use of at least one biodegradable, biocompatible poly(D,L-lactide) (PLA) and/or poly(D,L-lactide-co-glycolide) (PLGA) polymer and at least one liquid biodegradable non-polymeric excipient in the manufacture of a medicament for treating eye disorders and other diseases such as cancer.
